Omeros logo

Omeros Share Price (NASDAQ: OMER)

$4.16

-0.07

(-1.65%)

Last updated on

Check the interactive Omeros Stock chart to analyse performance

Omeros stock performance

as on August 30, 2025 at 1:29 am IST

  • Today's Low:$4.10
    Today's High:$4.23

    Day's Volatility :3.07%

  • 52 Weeks Low:$2.95
    52 Weeks High:$13.60

    52 Weeks Volatility :78.31%

Omeros Stock Returns

PeriodOmeros CorporationSector (Health Care)Index (Russel 2000)
3 Months
34.74%
3.6%
0.0%
6 Months
-49.2%
-7.7%
0.0%
1 Year
4.53%
-12.6%
0.0%
3 Years
-4.82%
10.2%
-4.1%

Omeros Corporation Key Stats

Check Omeros key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close
$4.23
Open
$4.22
Today's High
$4.23
Today's Low
$4.1
Market Capitalization
$287.9M
Today's Volume
$503.3K
52 Week High
$13.6
52 Week Low
$2.95
Revenue TTM
$-30.0M
EBITDA
$-137.4M
Earnings Per Share (EPS)
$-2.36
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-576.33%

Stock Returns calculator for Omeros Stock including INR - Dollar returns

The Omeros stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Omeros investment value today

Current value as on today

₹1,10,070

Returns

₹10,070

(+10.07%)

Returns from Omeros Stock

₹4,786 (+4.79%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Omeros Stock

5%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Omeros Stock from India on INDmoney has increased by 5% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Omeros Corporation

  • Name

    Holdings %

  • BlackRock Inc

    6.53%

  • Ingalls & Snyder LLC

    5.93%

  • Vanguard Group Inc

    4.89%

  • D. E. Shaw & Co LP

    2.45%

  • Stifel Financial Corp

    2.32%

  • Geode Capital Management, LLC

    2.04%

Analyst Recommendation on Omeros Stock

Rating
Trend

Buy

    66%Buy

    33%Hold

    0%Sell

Based on 9 Wall street analysts offering stock ratings for Omeros(by analysts ranked 0 to 5 stars)

Omeros Share Price Target

What analysts predicted

Upside of 440.87%

Target:

$22.50

Current:

$4.16

Omeros share price target is $22.50, a slight Upside of 440.87% compared to current price of $4.16 as per analysts' prediction.

Omeros Stock Insights

  • Price Movement

    In the last 6 months, OMER stock has moved down by -50.7%
  • OMER vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 69.9% return, outperforming this stock by 71.3%
  • OMER vs ALNY (3 yr)

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 116.0% return, outperforming this stock by 113.0%
  • Price to Sales

    ForOMER every $1 of sales, investors are willing to pay $-8.7, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.5 for every $1 of sales.

Omeros Technicals Summary

Sell

Neutral

Buy

Omeros is currently in a neutral trading position according to technical analysis indicators.

Omeros Corporation Vs Peers

Returns
Ratio's
Overview
Company Name1 Month6 Month1 Year3 Years5 Years
Omeros Corporation logo
14.96%
-49.2%
4.53%
-4.82%
-61.72%
Regeneron Pharmaceuticals, Inc. logo
3.92%
-15.2%
-50.31%
-3.3%
-2.01%
Beone Medicines Ltd logo
2.49%
24.81%
62.78%
79.11%
29.69%
Vertex Pharmaceuticals Incorporated logo
-15.42%
-19.13%
-17.84%
34.68%
41.87%
Alnylam Pharmaceuticals, Inc. logo
11.08%
83.28%
75.87%
111.28%
242.25%

About Omeros Corporation

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; zaltenibart that is in phase 3 clinical trials for Paroxysmal nocturnal hemoglobinuria; in phase 2 clinical trial for the treatment complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Immunostimulator Combination Therapies, and Oncotoxins and Immunomodulators for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
Organization
Omeros
Employees
202
CEO
Dr. Gregory A. Demopulos M.D.
Industry
Health Technology

Key Management of Omeros Corporation

NameTitle
Dr. Gregory A. Demopulos M.D.
Co-Founder, Chairman, CEO & President
Mr. David J. Borges
VP of Finance, Chief Accounting Officer & Treasurer
Mr. Peter B. Cancelmo J.D.
VP, General Counsel & Corporate Secretary
Dr. Pamela Pierce Palmer M.D., Ph.D.
Co-Founder
Dr. George A. Gaitanaris M.D., Ph.D.
Chief Scientific Officer & VP of Science
Mr. Peter W. Williams
Vice President of Human Resources
Dr. Catherine A. Melfi Ph.D.
Chief Regulatory Officer & VP of Regulatory Affairs and Quality Systems
Ms. Nadia Dac
VP & Chief Commercial Officer
Dr. Andreas Grauer M.D.
VP & Chief Medical Officer
Mr. David W. Ghesquiere
VP & Chief Business Development Officer

Important FAQs about investing in OMER Stock from India :

What is Omeros share price today?

Omeros share price today is $4.16 as on at the close of the market. Omeros share today touched a day high of $4.23 and a low of $4.10.

What is the 52 week high and 52 week low for Omeros share?

Omeros share touched a 52 week high of $13.60 and a 52 week low of $2.95. Omeros stock price today i.e. is closed at $4.16, lower by 69.41% versus the 52 week high.

How to invest in Omeros Stock (OMER) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Omeros on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Omeros Shares that will get you 0.3606 shares as per Omeros share price of $4.16 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Omeros Stock (OMER) from India?

Indian investors can start investing in Omeros (OMER) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Omeros stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Omeros share’s latest price of $4.16 as on August 30, 2025 at 1:29 am IST, you will get 2.4038 shares of Omeros. Learn more about fractional shares .

What are the returns that Omeros has given to Indian investors in the last 5 years?

Omeros stock has given -61.72% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?